Discover trends, market shifts, and competitive outlooks for the malignant pleural effusion industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research
What Are the Key Milestones in the Malignant Pleural Effusion Market’s Growth Trajectory From 2025 To 2034?
Recently, the market size for malignant pleural effusion has been significantly increasing. It is projected to expand from $4.42 billion in 2024 to $4.74 billion in 2025, with a compound annual growth rate (CAGR) of 7.1%. The growth noted during the historical period can be tied to the increased utilization of indwelling pleural catheters, enhanced emphasis on palliative care, a surge in clinical trials, an improvement in reimbursement programs, and an increase in metastatic malignancies.
In the coming years, the market size for malignant pleural effusion is predicted to experience robust growth. The forecast hints at a potential rise of up to $6.17 billion in 2029, with a compound annual growth rate (CAGR) of 6.8%. Factors contributing to this growth during the forecast period include enhanced healthcare infrastructure, increased government intervention, a growing number of cancer survivors, the rise in demand for home care, and advancements in liquid biopsy. The forecast period is also expected to witness significant trends such as the incorporation of AI in imaging technologies, innovations in cancer-specific therapies, advances in pleurodesis, the development of biomarkers, and the surge in clinical trials for innovative therapeutic agents.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=22047&type=smp
What are the Fundamental Drivers and Innovations Shaping the Malignant Pleural Effusion Market?
The escalation in lung cancer cases is set to fuel the expansion of the malignant pleural effusion market. Lung cancer, a malady distinguished by rampant cell proliferation in the lungs leading to tumor development, hinders standard lung functionality. The elevation in lung cancer instances is primarily a result of smoking and tobacco consumption, as prolonged exposure to the detrimental chemicals found in cigarettes wreaks havoc on lung tissues, instigates genetic anomalies, and incites the rampant proliferation of cancerous cells; thereby, significantly amplifying the possibility of contracting the disease. Malignant pleural effusion denotates late-stage lung cancer progression by speeding up tumorous dispersion within the pleural cavity, which leads to deteriorated respiratory function and a bleak prognosis. For instance, as per the American Cancer Society Facts and Figures —a professional US-based company— in January 2023, it was projected that the lung and bronchus cancer cases rose to 236,740 in 2022 and 238,340 in 2023 while estimated deaths were 130,180 in 2022 and 127,070 in 2023. Hence, the escalating lung cancer cases are steering the expansion of the malignant pleural effusion market. Owing to the enhanced diagnosis and treatment accessibility, the ameliorated healthcare infrastructure will further push the growth of the malignant pleural effusion market. The term healthcare infrastructure is used to describe the requisite physical, technological, and organizational structures for delivering healthcare facilities, encompassing hospitals, clinics, medical equipment, IT systems, and manpower. The need for improved disease management has led to the enhancement in healthcare infrastructure, culminating in boosted healthcare accessibility, efficacy, and quality of care. The upgraded healthcare infrastructure boosts the diagnosis, treatment, and management of malignant pleural effusion by facilitating access to state-of-the-art medical technologies, better furnished healthcare facilities, and specialized care; thereby, greatly improving patient outcomes. For instance, per the American Health Care Association —a non-profit organization based in the US— the quantity of hospitals in the United States rose by 0.591% from the previous year, ascending from 6,093 to 6,129 in May 2023. Therefore, the ameliorated healthcare infrastructure is steering the expansion of the malignant pleural effusion market.
How Is the Malignant Pleural Effusion Market Segmented?
The malignant pleural effusion market covered in this report is segmented –
1) By Treatment: Systemic Therapy, Therapeutic Thoracentesis, Thoracic Drainage And Pleurodesis, Indwelling Pleural Catheter
2) By Diagnosis: Pleural Fluid Cytology, Immunohistochemical Tests, Imaging Tests, Pleural Thoracentosis, Pleuroscopy, Pleural Biopsy
3) By End Users: Hospitals, Ambulatory Clinics, Other End Users
Subsegmentss:
1) By Systemic Therapy: Chemotherapy, Targeted Therapy, Immunotherapy
2) By Therapeutic Thoracentesis: Single-Time Thoracentesis, Repeated Thoracentesis
3) By Thoracic Drainage And Pleurodesis:Chemical Pleurodesis, Mechanical Pleurodesis, Biological Pleurodesis
4) By Indwelling Pleural Catheter:Tunneled Pleural Catheter, Non-Tunneled Pleural Catheter
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=22047&type=smp
Which Regions Are Driving the Next Phase of the Malignant Pleural Effusion Market Growth?
North America was the largest region in the malignant pleural effusion market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the malignant pleural effusion market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Key Trends Are Shaping the Future of the Malignant Pleural Effusion Market?
Leading companies in the malignant pleural effusion market are prioritising the development of trailblazing treatments like the enzyme-targeting therapy in order to enhance treatment results. This modality operates by pinpointing specific enzymes accountable for fluid accumulation. The prominence of enzyme-targeting therapy is observed in conditions such as cancer and infectious diseases where unusual enzyme activity escalates the disorder. Case in point, RS Oncology, LLC, a biotechnology firm based in the US, launched the MITOPE clinical trial in September 2022. Conducted in the UK, this pioneering Phase 1/2 trial examines RSO-021, an innovative PRX3 inhibitor that aims to tackle malignant pleural effusion and mesothelioma. It operates by targeting oxidative stress to eradicate cancer cells whilst conserving healthy tissue.
View the full report here:
https://www.thebusinessresearchcompany.com/report/malignant-pleural-effusion-global-market-report
How Is the Malignant Pleural Effusion Market Defined and What Are Its Core Parameters?
Malignant pleural effusion (MPE) refers to the accumulation of fluid in the pleural space due to the presence of cancer cells, typically resulting from metastatic disease. This condition occurs when cancer spreads to the pleura, the thin membrane surrounding the lungs, leading to increased vascular permeability and impaired lymphatic drainage.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22047
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
